Lp-PLA2: Inflammatory biomarker of vascular risk in multiple sclerosis

Journal of Clinical Immunology

Volumn 32, Issue 3, 2012, Pages 497-504

  Sternberg, Zohara ^a   Drake, Alison ^a   Sternberg, Daniel S ^a   Benedict, Ralph H B ^a   Li, Fan ^b   Hojnacki, David ^a   Weinstock Guttmann, Bianca ^a   Munschauer, Frederick E ^a  

^a JACOBS NEUROLOGICAL INSTITUTE   (United States)

^b the State University of New York   (United States)

Author keywords

Clinical relapse; lipid profiles; lipoprotein associated phospholipase A2; multiple sclerosis; relapsing remitting; secondary progressive; statins; vascular inflammation

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGE; ANALYTICAL PARAMETERS; ARTICLE; CHOLESTEROL BLOOD LEVEL; COLORIMETRY; CONTROLLED STUDY; DISABILITY SEVERITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PLASMA MASS; EXTENDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; MULTIPLE SCLEROSIS SEVERITY SCALE; PRIORITY JOURNAL; RATING SCALE; RELAPSE; RISK FACTOR; SCORING SYSTEM; VASCULITIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84861482114     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9642-3     Document Type: Article

References (40)

1. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol. 1995;15:1764-73.
2. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta. 2009;1791:327-38.
3. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005;25:923-31. (Pubitemid 40627835)
4. Caslake MJ, Packard CJ, Robertson M, Cooney J, Nelson JJ, Ford I, Gaw A, Jukema JW, Macfarlane PW, Stott DJ, Shepherd J. Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis. 2010;210:28-34.
5. Xu DL, Liu JN, Du YM, Yao GH, Jiang WD, Wang X, Dong ZQ, Hao L, Wang GY, Sui SJ, Li JF, Lu QH. The correlation of human serum Lp-PLA2 and hs-CRP and stability of coronary atherosclerotic plaques. Zhonghua Nei Ke Za Zhi. 2009;48:651-4.
6. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, Bohm BO, Marz W. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation. 2005;111:980-7. (Pubitemid 40354515)
7. Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, Lerman A, McConnell JP, Weintraub HS. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008;101:51F-7.
8. Shi Y, Zhang P, Zhang L, Osman H, Mohler 3rd ER, Macphee C, Zalewski A, Postle A,Wilensky RL. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis. 2007;191:54-62. (Pubitemid 46227429)
9. Rezai-Zadeh K, Gate D, Town T. CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol. 2009;4:462-75.
10. Sternberg Z, Chadha K, Lieberman A, Hojnacki D, Drake A, Zamboni P, Rocco P, Grazioli E,Weinstock-Guttman B,Munschauer F. Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. J Neuroimmunol. 2008;205:142-7.
11. Lucas M, Sanchez-Solino O, Solano F, Izquierdo G. Interferon beta-1b inhibits reactive oxygen species production in peripheral blood monocytes of patients with relapsing-remitting multiple sclerosis. Neurochem Int. 1998;33:101-2. (Pubitemid 28410133)
12. Turunen P, Jalkanen J, Heikura T, Puhakka H, Karppi J, Nyyssonen K, Yla-Herttuala S. Adenovirus-mediated gene transfer of Lp-PLA2 reduces LDL degradation and foam cell formation in vitro. J Lipid Res. 2004;45:1633-9. (Pubitemid 39296202)
13. Naidoo R, Knapp ML. Studies of lipid peroxidation products in cerebrospinal fluid and serum in multiple sclerosis and other conditions. Clin Chem. 1992;38:2449-54. (Pubitemid 23006211)
14. Newcombe J, Li H, Cuzner ML. Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: implications for pathogenesis. Neuropathol Appl Neurobiol. 1994;20:152-62. (Pubitemid 24123546)
15. Qin J, Goswami R, Balabanov R, Dawson G. Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J Neurosci Res. 2007;85:977-84. (Pubitemid 46580339)
16. Schmitz G, Ruebsaamen K. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis. 2010;208:10-8.
17. Wootton PT, Stephens JW, Hurel SJ, Durand H, Cooper J, Ninio E, Humphries SE, Talmud PJ. Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus. Atherosclerosis. 2006;189:149-56. (Pubitemid 44441290)
18. Ky B, Burke A, Tsimikas S, Wolfe ML, Tadesse MG, Szapary PO, Witztum JL, FitzGerald GA, Rader DJ. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol. 2008;51:1653-62. (Pubitemid 351626406)
19. Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, Elisaf M, Tselepis AD. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007;27:2236-43. (Pubitemid 350287255)
20. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006;26:1586-93. (Pubitemid 44288987)
21. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999;5:244-50. (Pubitemid 29405620)
22. Rudick RA, Lee JC, Nakamura K, Fisher E. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci. 2009;282(1-2):106-11.
23. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26:137-44. (Pubitemid 40282781)
24. Calabrese M, De Stefano N, Atzori M, Bernardi V, Mattisi I, Barachino L, Morra A, Rinaldi L, Romualdi C, Perini P, Battistin L, Gallo P. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol. 2007;64:1416-22. (Pubitemid 47572665)
25. Tselepis AD, Elisaf M, Besis S, Karabina SA, Chapman MJ, Siamopoulou A. Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity. Arthritis Rheum. 1999;42:373-83. (Pubitemid 29072856)
26. Tetta C, Bussolino F, Modena V, Montrucchio G, Segoloni G, Pescarmona G, Camussi G. Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol. 1990;91:244-56. (Pubitemid 20182314)
27. Sternberg Z, Weinstock-Guttman B, Hojnacki D, Zamboni P, Zivadinov R, Chadha K, Lieberman A, Kazim L, Drake A, Rocco P, Grazioli E, Munschauer F. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult Scler. 2008;14:759-63.
28. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, Hooper S, Le Trong H, Cousens LS, Zimmerman GA, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 1995;374:549-53.
29. Cao Y, Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J Biol Chem. 1998;273:4012-20. (Pubitemid 28103265)
30. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423.
31. Neuhaus O, Hartung HP. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert Rev Neurother. 2007;7:547-56. (Pubitemid 46743446)
32. Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002;3:57-68. (Pubitemid 38234487)
33. Mannheim D, Herrmann J, Versari D, Gossl M, Meyer FB, McConnell JP, Lerman LO, Lerman A. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke. 2008;39:1448-55.
34. Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Miltiadous G, Goudevenos JA, Cariolou MA, Chapman MJ, Tselepis AD, Elisaf M. Altered distribution of plateletactivating factor acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res. 2002;43:256-63. (Pubitemid 34184012)
35. Braun LT, Davidson MH. Lp-PLA2: a new target for statin therapy. Curr Atheroscler Rep. 2010;12:29-33.
36. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res: The off J Am Soc Bone Miner Res. 2000;15:599-604.
37. Tselepis AD, Karabina SA, Stengel D, Piedagnel R, Chapman MJ, Ninio E. N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL. J Lipid Res. 2001;42:1645-54. (Pubitemid 33020097)
38. Sternberg Z,Hennies C, SternbergD, BistulfiGL, KazimL, Benedict RH, Chadha K, Leung C, Weinstock-Guttman B, Munschauer F. Plasma pentosidine: a potential biomarker in the management of multiple sclerosis. Mult Scler. 2011;17:157-63.
39. Sternberg Z, Hennies C, Sternberg D, Wang P, Kinkel P, Hojnacki D, Weinstock-Guttmann B, Munschauer F. Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosis. J Neuroinflammation. 2010;7:72.
40. White H. Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes. Curr Opin Cardiol. 2010;25:299-301.